Overall safety profile of boceprevir plus peginterferon alfa‐2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
Year: 2013
Type: article
Source: Liver International
DOI: 10.1111/liv.12300
Authors: Michael P. Manns, Jonathan McCone, Mitchell N. Davis, Lorenzo Rossaro, Eugene Schiff, Mitchel L. Shiffman, Bruce Bacon, Marc Bourliere, Mark S. Sulkowski, Savino Bruno, Luis Balart, Jean‐Pierre Bronowicki, Paul Kwo, Fred Poordad, Franco Felizarta, K. Rajender Reddy, Frans A. Helmond, Heather L. Sings, Lisa D. Pedicone, Margaret Burroughs, Clifford A. Brass, Janice K. Albrecht, John M. Vierling
Institutions: Medizinische Hochschule Hannover, Digestive CARE, University of California Davis Medical Center, University of California, Davis, University of Miami, Bon Secours Health System, Saint Louis University, Hôpital Saint Joseph, Johns Hopkins University, Johns Hopkins Medicine, Azienda Ospedaliera Fatebenefratelli e Oftalmico, Tulane University, Inserm, Centre Hospitalier Régional et Universitaire de Nancy, Nutrition-Génétique et Exposition aux Risques Environnementaux, Université de Lorraine, Indiana University Indianapolis, Indiana University School of Medicine, Cedars-Sinai Medical Center, Texas Liver Institute, Pennsylvania State University, University of Pennsylvania, Merck & Co., Inc., Rahway, NJ, USA (United States), Baylor College of Medicine
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Award: G2456272280
OpenAlex ID: W2053655447